Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133363 | 1.00 | L3MBTL1 (0.58) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL135177 | 1.00 | L3MBTL1 (0.58) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| Methylene Chloride SCHEMBL28081516 | 0.95 | POLB (0.53) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL282976 | 0.95 | POLB (0.51) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL282977 | 0.95 | POLB (0.51) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL192841 | 0.95 | POLB (0.51) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31323435 | 0.94 | POLB (0.50) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31048468 | 0.94 | POLB (0.50) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL20399730 | 0.94 | POLB (0.50) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL3769601 | 0.93 | HPGD (0.54) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111790439-B | Chiral secondary amine diphenylphosphine arylformamide bifunctional catalyst and preparation method and application thereof | 成都能特科技发展有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-114920683-A | Preparation method of Boc-prolinaldehyde and (R, E) - (1-methylpyrrolidine-2-yl) acrylic acid | 苏州富士莱医药股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-111790439-A | Chiral secondary amine diphenylphosphine arylformamide bifunctional catalyst and preparation method and application thereof | 南宁师范大学 | 2020-10-20 | — | — | CN | claimed |
| CN-103044311-B | Multi-substituted indole compounds and preparation method and application thereof | UNIV SHANDONG | 2015-04-22 | — | — | CN | claimed |
| CN-103044311-A | Multi-substituted indole compounds and preparation method and application thereof | UNIV SHANDONG | 2013-04-17 | — | — | CN | claimed |
| WO-2011011598-A1 | PROCESS FOR PREPARING 4- { (S) -2- (4-(4-CHLOROPHENOXY) PHENOXYMETHYL) PYRROLIDIN-1-YL) } BUTYRIC ACID AND SALTS THEREOF | DECODE GENETICS EHF (IS) | 2011-01-27 | — | — | WO | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12583887-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0324993-A1 | Sparsomicin (Sc-Rs) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (Sc-Rs) compounds | Stichting Katholieke Universiteit (NL) | 1989-07-26 | — | — | EP | disclosed |
| US-4820712-A | Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 1989-04-11 | — | — | US | disclosed |
| EP-0207420-A2 | Pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | L3MBTL1 3074/4885POLB 2333/4885HSD17B10 3711/4885 |
| US-12583887-B2 | PSMA imaging agents | KLK3, PSMA3, PSMA1 | L3MBTL1 3753/4885POLB 3904/4885HSD17B10 1995/4885 |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | KRAS, MYC, NRAS | L3MBTL1 1458/4885POLB 906/4885HSD17B10 3043/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | L3MBTL1 1207/4885POLB 4039/4885HSD17B10 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.